abstract: IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER: T-cell-directed strategies represent currently a major advance in the treatment of advanced non-small-cell lung cancer, regarding their efficacy and tolerance. Nivolumab and pembrolizumab, two monoclonal antibodies targeting programmed cell death protein 1 (PD-1) have shown their efficacy in phase III studies. Several other drugs are developed and the benefit of association is being evaluated. In this article, we propose to summarize the clinical development of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
authors.affiliation: INSERM UMR-S1147, université Sorbonne-Paris-Cité, Paris, France; Service d'oncologie médicale, hôpital européen Georges-Pompidou (HEGP), Assistance publique-hôpitaux de Paris, Paris, France. Electronic address: elizabeth.fabre@aphp.fr.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fabre
authors.affiliation: INSERM UMR-S1147, université Sorbonne-Paris-Cité, Paris, France; Service d'oncologie médicale, hôpital européen Georges-Pompidou (HEGP), Assistance publique-hôpitaux de Paris, Paris, France.
authors.forename: Nicola
authors.initials: N
authors.lastname: Pécuchet
authors.affiliation: Service de pneumologie, hôpital Tenon, Assistance publique-hôpitaux de Paris, France; GRC 04, Theranoscan, université Pierre-et-Marie-Curie, Paris 6, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059447:Cell Cycle Checkpoints / Q000187:drug effects* / Q000276:immunology; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab; C582435:pembrolizumab
keywords: Cancer bronchique non à; Immunotherapy; Immunothérapie; Non-small-cell lung cancer; PD-1; PD-L1; petites cellules